P.101 Baseline characteristics/initial safety in RESPOND: phase 4 study of nusinersen in children with SMA who previously received onasemnogene abeparvovec

Neuromuscular Disorders - Tập 32 - Trang S86 - 2022
C. Proud1, J. Parsons2, R. Masson3, J. Brandsema4, R. Finkel5, K. Swoboda6, E. Finanger7, Y. Liu8, C. Makepeace9, A. Paradis8, Z. Berger8, J. Wagner8, K. Somera-Molina8
1Children’s Hospital of the King’s Daughters, Norfolk, USA
2Children's Hospital Colorado, Aurora, USA
3Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
4Children’s Hospital of Philadelphia, Philadelphia, USA
5St. Jude Children's Research Hospital, Memphis, USA
6Massachusetts General Hospital, Boston, USA
7Oregon Health and Science University, Portland, USA
8Biogen, Cambridge, USA
9Biogen, Maidenhead, USA

Thông tin
Thông tin xuất bản

Neuromuscular Disorders

Tập 32

S86

Thông tin tác giả